Abstract
BackgroundMarkov models are a key tool for calculating expected time spent in a state, such as active life expectancy and disabled life expectancy. In reality, individuals often enter and exit states recurrently, but standard analytical approaches are not able to describe this dynamic. We develop an analytical matrix approach to calculating the expected number and length of episodes spent in a state.MethodsThe approach we propose is based on Markov chains with rewards. It allows us to identify the number of entries into a state and to calculate the average length of episodes as total time in a state divided by the number of entries. For sampling variance estimation, we employ the block bootstrap. Two case studies that are based on published literature illustrate how our methods can provide new insights into disability dynamics.ResultsThe first application uses a classic textbook example on prednisone treatment and liver functioning among liver cirrhosis patients. We replicate well-known results of no association between treatment and survival or recovery. Our analysis of the episodes of normal liver functioning delivers the new insight that the treatment reduced the likelihood of relapse and extended episodes of normal liver functioning. The second application assesses frailty and disability among elderly people. We replicate the prior finding that frail individuals have longer life expectancy in disability. As a novel finding, we document that frail individuals experience three times as many episodes of disability that were on average twice as long as the episodes of nonfrail individuals.ConclusionsWe provide a simple analytical approach for calculating the number and length of episodes in Markov chain models. The results allow a description of the transition dynamics that goes beyond the results that can be obtained using standard tools for Markov chains. Empirical applications using published data illustrate how the new method is helpful in unraveling the dynamics of the modeled process.
Highlights
Markov models are a key tool for calculating expected time spent in a state, such as active life expectancy and disabled life expectancy
Using a discrete-time, homogeneous Markov chain with finite state space, we show how a general method for Markov chains with rewards presented by van Daalen and Caswell [19] and recently discussed in this journal by Caswell and Zarulli [20] can be used for the calculation of the expected number and length of episodes spent in a state
Prednisone, a steroid hormone that was discovered in the 1950s, has been used in the treatment of cirrhosis complications
Summary
Markov models are a key tool for calculating expected time spent in a state, such as active life expectancy and disabled life expectancy. In epidemiological and health research, Markov chains and other Markov models are, for example, often used to analyze active life expectancy and disability-free life expectancy [5,6,7,8], or life expectancy spent with or without specific conditions [9,10,11,12]. While it can be safely assumed that some transitions occur only once—i.e., that the expected time in the state equals the length of the episode—in other cases a large number of repeated transitions to and from a state are possible This has been shown to be the case for frailty and disability [15, 16]. Mostly simulation methods were used for assessing this dynamic aspect of Markov processes [17], and analytical solutions have been limited to specific cases [18]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
